{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Psychedelic News Feed","title":"Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing","html":"","width":"100%","height":180,"duration":1031,"description":"In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:\nEarly Notes from The Psychedelic Healthcare Forum\nFDA Floats an Ibogaine Trial Design, Asks Field for Input\nCompass Talks Pricing, Label and a Slow Launch\nNew Mexico Nears Medical Psilocybin Launch\nSix More Potential Psychedelic Brand Names\n\nRead more:\nPα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names\nThe Psychedelic Practitioner Issue 7: Preparedness (Systems) \n\nThe Psychedelic News Feed is published by Psychedelic Alpha and airs every two weeks.\n\nThis episode of The Psychedelic News Feed is supported by UBC. As psychedelic therapies move toward potential approvals, UBC helps sponsors navigate the evidence generation, pharmacovigilance, and comprehensive risk management strategies that support a path forward grounded in patient safety. Learn more at ubc.com.\n\nSend us your questions and comments at pod@psychedelicalpha.com \n\nRead more and join our newsletter at https://psychedelicalpha.com\n\nFollow us on Instagram @psychedelicalpha, X @Psyched_Alpha, and LinkedIn.\n\nSubscribe to Pα+ for premium insights: https://psychedelicalpha.com/join/ ","thumbnail_url":"https://img.transistorcdn.com/JloIlpLTBLPjk3I75jU_cRq8srB2BvAcUvjRPrSEM2M/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS83MDc4/NWQ1YzQ4ODk0YjVm/NzE0OWNlOTkyOWI5/MTU3OC5wbmc.webp","thumbnail_width":300,"thumbnail_height":300}